Does multiple myeloma response induction therapy depending on plasma cell il6 receptor gene expression
Keywords:
Multiple myeloma, Quantitative PCr, oncogenesis, treatment resistance, cytokines.Abstract
Background: Interleukine 6 (IL-6) is the most important cytokine involved in malignant plasma cells growth and survival.aim: To analyse bone marrow plasma cells IL6 receptor gene expression in both multiple myeloma patients at diagnosis and healthy bone marrow donors.
methods: Clinical and biological patients’ features and responses to Dexamethasone-Thalidomide induction therapy were gathered. 47 patients and 16 case controls were analyzed: Bone marrow plasma cells were isolated; and IL6 receptor gene expression was quantified using Taqman quantitative PCr technology and 2-ΔCT formula.
results: Quantitative and qualitative IL6 receptor gene expression were negatively correlated with the degree of response to therapy (p= 0.02). In this study, plasma cells IL6 receptor gene expression seems to be decisive in predicting the response to treatment.
Conclusion: Understanding the mechanisms involved in plasma cells IL6 receptor gene expression may offer a better appreciation of the physiopathologic and anti-oncogenic ways of drug resistance in multiple myeloma and consequently the discovery of new specific drugs.
Downloads
References
Kyle rA, rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
Klein B, Zhang XG, Lu ZY, Bataille r. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-26.
Seon Young Kim, Hyun Jung Min, alHyun Kyung Park Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation Biol Blood Marrow Transplant 2011; 17 : 810-20.
Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
Gaillard JP, Bataille r, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-4.
Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77:2794-5.
Barillé S, Collette M, Bataille r, Amiot M. Myeloma cells up regulate interleukin-6 secretion in osteoblastic cells through cellto- cell contact but down regulate osteocalcin. Blood. 1995;86:3151-9.
Tassone P, Neri P, Burger r, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer res 2005;11:4251-8.
